Ladarixin

Summary

Ladarixin (CHEMBL189475) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including type 1 diabetes mellitus and bullous pemphigoid.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 9
• Chemistry: 375.3 Da · C11H12F3NO6S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL189475
Name	Ladarixin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	11372270
Molecular formula	C11H12F3NO6S2
Molecular weight	375.3
InChIKey	DDLPYOCJHQSVSZ-SSDOTTSWSA-N

SMILES: C[C@H](C1=CC=C(C=C1)OS(=O)(=O)C(F)(F)F)C(=O)NS(=O)(=O)C

IUPAC name: [4-[(2R)-1-(methanesulfonamido)-1-oxopropan-2-yl]phenyl] trifluoromethanesulfonate

Also known as: Df2156a, Ladarixin, Ladarixina, Ladarixine, LADARIXIN, Ladarixin sodiumÊ, Ladarixin sodiumÂ

Parent form; salt/anhydrous children: CHEMBL4442431

Patent coverage: 73 distinct patent families (187 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: C-X-C chemokine receptor type 2.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CXCR2	9.15	IC50	0.7	nM	CHEMBL_ACT_25709887

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
type 1 diabetes mellitus	3	MONDO:0005147	MONDO:0005147
bullous pemphigoid	2	MONDO:0019082	EFO:0007187
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE2	7
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01571895	PHASE2	TERMINATED	Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid
NCT02814838	PHASE2	COMPLETED	A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes
NCT04628481	PHASE2	TERMINATED	A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function
NCT04899271	PHASE2	TERMINATED	A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.
NCT05035368	PHASE2	WITHDRAWN	Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes
NCT05368402	PHASE2	TERMINATED	Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.
NCT05815186	PHASE2	WITHDRAWN	Ladarixin With Sotorasib in Advanced NSCLC - Phase II
NCT05815173	PHASE1	RECRUITING	Ladarixin With Sotorasib in Advanced NSCLC
NCT04854642	PHASE1	COMPLETED	A Single Dose Study About the Influence of Food on the Oral Bioavailability of Ladarixin Capsule in Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).